Are there specific points in the signaling cascade that are safer to target in populations at risk for recurrent schistosomiasis infection, such as TSP-1?Do conventional PAH treatments work in SchPAH to the same degree as in IPAH?What are drug targets in SchPAH that address the underlying pathogenic mechanisms, such as HSS versus other pathways to SchPAH?Are there specific targets in SchPAH that would also benefit other forms of PAH? This evidence concerns the gene THBS1 and pulmonary arterial hypertension.